Evommune (EVMN) Non Operating Income (2024 - 2026)

Evommune (EVMN) has 3 years of Non Operating Income data on file, last reported at $2.3 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $2.3 million, up 380.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 million (changed N/A YoY), and the FY2025 annual result was $12.2 million, up 280.69% from the prior year.
• Non Operating Income improved to $2.3 million in Q1 2026 per EVMN's latest filing, from $1.4 million in the prior quarter.
• Over five years, Non Operating Income peaked at $2.3 million in Q1 2026 and troughed at $475000.0 in Q1 2025.
• A 3-year average of $1.1 million and a median of $790500.0 in 2024 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2025 and 2026: Non Operating Income surged 41.93% in 2025, then surged 380.0% in 2026.
• A 3-year view of Non Operating Income shows it stood at $728000.0 in 2024, then jumped by 98.21% to $1.4 million in 2025, then jumped by 58.0% to $2.3 million in 2026.
• Business Quant data shows EVMN's Non Operating Income at $2.3 million in Q1 2026, $1.4 million in Q4 2025, and $853000.0 in Q3 2025.